摘要
目的：探讨甲状腺癌患者糖基化磷脂酰肌醇特异性磷脂酶D（GPI-PLD）的活性变化,为甲状腺癌患者的诊断提供依据.方法：利用具有糖基化磷脂酰肌醇（GPI） 结构的胎盘碱性磷酸酶（PLAP）做底物,通过TX-114分相,定量检测外周血单个核细胞和血浆中GPI-PLD活性,并采用荧光定量PCR外周血单个核细胞中GPI-PLD mRNA水平,分析其表达量与甲状腺癌之间的关系.结果：甲状腺癌患者外周血单个核细胞和血浆中GPI-PLD酶活性分别为（24.15±2.33）%和（29.71±1.52）%,明显低于正常外周血中GPI-PLD酶活性（P＜0.001）,且甲状腺癌患者单个核细胞GPI-PLD活性仅为其血浆中酶活性水平的81.29%,二者之间有显著性差异（P〈0.05）;甲状腺癌患者外周血单个核细胞中GPI-PLD mRNA表达平均值为（0.46±0.17）×10^3copy/ng total RNA,明显低于正常人外周血单个核细胞中的表达水平（1.35±0.41）×10^3copy/ng total RNA （P＜0.001）.结论：GPI-PLD在甲状腺癌患者中活性及表达明显降低,有可能作为甲状腺癌诊断的指标之一.
Objective Discussion of thyroid carcinoma in patients with advanced glycation phosphatidylinositol- specific phospholipase D （GPI- PLD） activity changes to provide a basis for judging the prognosis. Methods With the use of advanced glycation phosphatidylinositol （GPI） structure of the placental alkaline phosphatase （PLAP） substrate to do through the TX-114 phase, the quantitative detection of peripheral blood mononuclear cells and plasma GPI-PLD activity and FQ-PCR using peripheral blood mononuclear cells in GPI-PLD mRNA level of analysis of their expression and the relationship between thyroid carcinoma. Results Patients with thyroid carcinoma in peripheral blood mononuclear cells and plasma GPI-PLD activity were （24.15± 2.33） % and （29.71 ± 1.52） %, significantly lower than in the peripheral blood GPI-PLD activity （ P 〈0. 001）, and patients with thyroid carcinoma mononuclear Cell GPI-PLD activity was only the plasma level of activity of 81.29 percent, between the difference was significant （ P 〈0.05） ; Patients with thyroid carcinoma in peripheral blood mononuclear cells GPI-PLD mRNA expression for the average of（0.46 ±0. 17） × 10^3eopy/ng total RNA, significantly lower than the normal human peripheral blood mononuclear ceils of expression（1. 35±0.41） × 10^3copy/ ng total RNA （ P〈0. 001）. Conclusions GPI-PLD activity in thyroid carcinoma patients and significantly reduced the expression, it is possible to determine the prognosis of thyroid carcinoma as one of the indicators.
